Thus, this analysis of modulated signaling indicates that the identified functional alterations were not revealed by surface phenotyping and were not due to differences in levels of expression of receptor molecules for the IL-17 ligands, but instead resulted from altered functional signaling capacity in the B-CLL cells. The gene discussed is IL17A; the disease is B-cell chronic lymphocytic leukemia.